CVS Health Surges to 161st in Trading Volume with $830 Million in Shares Traded Despite Stock Price Decline

On April 3, 2025, CVS Health (NYSE: CVS) experienced a significant increase in trading volume, with a total of $830 million in shares traded, marking a 90.75% rise from the previous day. This surge placed CVS at the 161st position in terms of trading volume for the day. However, despite the high trading volume, the stock price of CVS Health declined by 0.82%.

CVS Health is scheduled to hold a conference call with analysts and investors on Thursday, May 1st, 2025, at 8:00 a.m. ET. The call will focus on discussing the company's first-quarter 2025 earnings and financial performance. This event is expected to provide valuable insights into CVS Health's recent operations and future outlook, which could influence investor sentiment and potentially impact the stock price.

In a significant development for Parkinson's disease patients, CVS Health has expanded its coverage for CREXONT® (carbidopa and levodopa), a medication approved by the U.S. FDA in 2024. The drug has been added to the national prescription drug formularies of three major insurance providers: the Veterans Administration, UnitedHealthcare, and CVS Health itself. This expansion increases the total U.S. insurance coverage for CREXONT from about 30% to over 50% of covered lives, surpassing the company's initial goal of achieving this milestone by the end of 2025. The Veterans Administration has already included CREXONT in its national formulary, covering approximately 10% of U.S. Parkinson's disease patients. UnitedHealthcare will add CREXONT to its standard prescription drug lists in the second quarter of 2025, while CVS Health will include it as a "preferred" product in its national formulary starting July 1, 2025. This expanded coverage is expected to enhance access to CREXONT for Parkinson's disease patients, potentially driving increased demand for the medication and positively impacting CVS Health's revenue streams.